- Home
- SPPL vs HCWB Comparison
SPPL vs HCWB Comparison
Compare SPPL & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- HCWB
- Stock Information
- Founded
- SPPL 2016
- HCWB 2018
- Country
- SPPL Singapore
- HCWB United States
- Employees
- SPPL N/A
- HCWB N/A
- Industry
- SPPL
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- HCWB Health Care
- Exchange
- SPPL Nasdaq
- HCWB Nasdaq
- Market Cap
- SPPL 9.8M
- HCWB 8.4M
- IPO Year
- SPPL 2023
- HCWB 2021
- Fundamental
- Price
- SPPL $3.50
- HCWB $4.26
- Analyst Decision
- SPPL
- HCWB Strong Buy
- Analyst Count
- SPPL 0
- HCWB 1
- Target Price
- SPPL N/A
- HCWB $35.00
- AVG Volume (30 Days)
- SPPL 43.2K
- HCWB 305.3K
- Earning Date
- SPPL 01-01-0001
- HCWB 08-13-2025
- Dividend Yield
- SPPL N/A
- HCWB N/A
- EPS Growth
- SPPL N/A
- HCWB N/A
- EPS
- SPPL N/A
- HCWB N/A
- Revenue
- SPPL $2,764,846.00
- HCWB $1,445,145.00
- Revenue This Year
- SPPL N/A
- HCWB $178.36
- Revenue Next Year
- SPPL N/A
- HCWB N/A
- P/E Ratio
- SPPL N/A
- HCWB N/A
- Revenue Growth
- SPPL N/A
- HCWB N/A
- 52 Week Low
- SPPL $2.02
- HCWB $3.55
- 52 Week High
- SPPL $16.80
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- SPPL 60.28
- HCWB 40.26
- Support Level
- SPPL $3.01
- HCWB $4.10
- Resistance Level
- SPPL $3.45
- HCWB $4.49
- Average True Range (ATR)
- SPPL 0.34
- HCWB 0.31
- MACD
- SPPL 0.03
- HCWB 0.09
- Stochastic Oscillator
- SPPL 56.60
- HCWB 27.30
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.